Published in Gene Therapy Weekly, September 29th, 2005
Study 1: Scientists report the results of immune monitoring in a phase 1 trial of a prostate-specific antigen (PSA) DNA vaccine in patients with hormone-refractory prostate cancer.
According to a study from Sweden, "Prostate cancer remains a leading cause of cancer illness and death among men in Europe. No curative treatment exists when the disease has spread beyond the prostate. Immunotherapy with DNA vaccines has emerged as a potential therapeutic approach for the induction of antitumor specific cytotoxic T lymphocytes."
"In this study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-09-29)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.